General
Preferred name
IMARADENANT
Synonyms
HTL1071 ()
AZD-4635 (HTL1071) ()
AZD4635 ()
Imaradenant (AZD4635) ()
AZD-4635 ()
HTL-1071 ()
AZD 4635 ()
P&D ID
PD078547
CAS
1321514-06-0
Tags
available
probe
drug candidate
Drug indication
non-small cell lung carcinoma
Prostate cancer
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Probe info
Probe type
P&D approved
experimental probe
Probe selectivity
protein-selective
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
7
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
AZD4635 (HTL1071) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a Ki of 1.7 nM and shows >30-fold selectivity over other adenosine receptors[1].
PRICE
84
DESCRIPTION
Imaradenant (AZD4635) is an orally bioavailable adenosine A2A receptor (A2AR) antagonist . It was developed as a potential immuno-oncology (immunotherapy) drug. Imaradenant reduces the immunosuppressive effects of adenosine within the tumour microenvironment, an activity that rescues immune cell function and it enhances the efficacy of checkpoint inhibitors in syngeneic mouse tumour models .
In 2021 AstraZeneca decided to stop a number of their midphase studies of imaradenant in patients with prostate cancer. (GtoPdb)
In 2021 AstraZeneca decided to stop a number of their midphase studies of imaradenant in patients with prostate cancer. (GtoPdb)
MOA
Antagonist
(Chemical Probes.org)
DESCRIPTION
AZD4635 (HTL1071) is a new-type adenosine 2A receptor (A2AR) inhibitor(Ki=1.7 nM).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical Probes.org
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
High-quality chemical probes
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
14
Molecular Weight
315.07
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
3
cLogP
3.28
TPSA
77.58
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
A2A
Adenosine Receptor
ADORA2A
MOA
Adenosine Receptor antagonist
Pathway
GPCR/G protein
Neuroscience
Target class
GPCR
Source data
